Insight: 2026 May See a "Crypto Winter," but Institutionalization and On-chain Transformation are Accelerating
BlockBeats News, December 29th, Cantor Fitzgerald pointed out in its latest year-end report that Bitcoin may be entering a prolonged multi-month downward cycle, with the market possibly stepping into an early "crypto winter" in 2026. Analyst Brett Knoblauch believes that Bitcoin has fallen back from this cycle's peak for about 85 days, and the price may continue to be under pressure, even testing the Strategy's average cost line around $75,000.
However, unlike previous cycles, this downward cycle is unlikely to be accompanied by a large-scale liquidation or systemic collapse. Cantor notes that the current market is dominated by institutions rather than retail investors, and the "divergence" between token price performance and on-chain fundamentals is widening, especially in the DeFi, tokenized assets, and crypto infrastructure sectors.
On the regulatory front, the passage of the U.S. "Digital Asset Market Structure Clarity Act" is seen as a key turning point, expected to reduce policy uncertainty and drive banks and asset management institutions to more deeply engage in the crypto market.
Cantor concluded that although 2026 may not usher in a new bull market, the institutionalization of the crypto industry, compliance pathways, and on-chain infrastructure are gradually solidifying while the price cools down.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Janus Henderson Macro Head Says Market Is Near Its Top but Cannot Say When
A $5.7 billion patent verdict has been issued, Burford Capital (BUR.US) may receive $1.4 billion, and its share price soared by more than 12%.
Burford Capital Ltd. surged more than 12% on Monday, marking its largest intraday increase since the end of March, after a federal jury delivered a verdict in a patent case involving Apple.
Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request
A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.
After years of waiting and another delay, Tesla (TSLA.US) postpones the Roadster debut to October 15 as severe weather forces the event to stop.
Tesla has rescheduled the unveiling event for its next-generation Roadster, originally planned for this week, to October 15.
